Advanced

AJNR - American Journal of Neuroradiology

Published ahead of print on January 9, 2008
doi: 10.3174/ajnr.A0905

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: ajnr.A0905v1 29/4/668    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bleicher, A.G. Articles by Kanal, E. Search for Related Content PubMed PubMed Citation Articles by Bleicher, A.G. Articles by Kanal, E.

American Journal of Neuroradiology 29:668-673, April 2008
© 2008 American Society of Neuroradiology

BRAIN

A Serial Dilution Study of Gadolinium-Based MR Imaging Contrast Agents

A.G. Bleicher^a and E. Kanal^a

^a From the Department of Radiology, Division of Neuroradiology, the University of Pittsburgh Medical Center, Pittsburgh, Pa

Please address correspondence to Andrew G. Bleicher, MD, University of Pittsburgh Medical Center, Department of Radiology, Division of Neuroradiology, 200 Lothrop St, Room D-132, Pittsburgh, PA 15213; e-mail: bleicherag{at}upmc.edu

BACKGROUND AND PURPOSE: With the approval of gadobenate dimeglumine, higher relaxivity MR contrast agents were introduced into the clinical environment, and multiple in vivo studies compared the efficacy and safety with the previously approved agents. An in vitro study was conducted to demonstrate differences between the various agents to confirm published values and for imaging-sequence optimization.

MATERIALS AND METHODS: A contrast phantom was made with serial dilutions of commercially available formulations of 5 US Food and Drug Administration–approved gadolinium-based MR imaging contrast agents in human serum substitute. Dilution factors ranging from 1:8 to 1:4096 were included in the phantom. Spin-echo sequences were performed at 1.5T and 3T with varying TRs and TEs.

RESULTS: At physiologic concentrations and by using short TRs and TEs, gadobenate demonstrated the highest signal intensities, confirming greater R1 relaxivity. At higher concentrations and with longer TR and TE values, the greatest signal intensity loss was appreciated for gadobenate, confirming greater R2 relaxivity.

CONCLUSION: Using rigorous in vitro methodology and serial dilution techniques, this study confirms the reported higher R1 and R2 relaxivities of gadobenate relative to the other agents at 1.5T and 3T.

This article has been cited by other articles:

				H.A. Rowley, G. Scialfa, P.-y. Gao, J.A. Maldjian, D. Hassell, M.J. Kuhn, F.J. Wippold II, M. Gallucci, B.C. Bowen, I.M. Schmalfuss, et al. Contrast-Enhanced MR Imaging of Brain Lesions: A Large-Scale Intraindividual Crossover Comparison of Gadobenate Dimeglumine versus Gadodiamide AJNR Am. J. Neuroradiol., October 1, 2008; 29(9): 1684 - 1691. [Abstract] [Full Text] [PDF]